Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label，single-arm, phase II exploratory study that evaluates the efficacy and
safety of Camrelizumab combined with Chemotherapy （carboplatin or cisplatin + etoposide）and
Apatinib as First Line treatment in Advanced or Metastatic Extrapulmonary Neuroendocrine
Carcinomas（EP-NEC）